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Arrhythmogenic cardiomyopathy (ACM) is an inherited arrhythmia syndrome characterized
by severe structural and electrical cardiac phenotypes, including myocardial fibrofatty
replacement and sudden cardiac death. Clinical management of ACM is largely palliative,
owing to an absence of therapies that target its underlying pathophysiology, which stems
partially from our limited insight into the condition. Following identification of deceased ACM
probands possessing ANK2 rare variants and evidence of ankyrin-B loss of function on
cardiac tissue analysis, an ANK2 mouse model was found to develop dramatic structural
abnormalities reflective of human ACM, including biventricular dilation, reduced ejection
fraction, cardiac fibrosis, and premature death. Desmosomal structure and function
appeared preserved in diseased human and murine specimens in the presence of markedly
abnormal b-catenin expression and patterning, leading to identification of a previously
unknown interaction between ankyrin-B and b-catenin. A pharmacological activator of the
WNT/b-catenin pathway, SB-216763, successfully prevented and partially reversed the
murine ACM phenotypes. Our findings introduce what we believe to be a new pathway for
ACM, a role of ankyrin-B in cardiac structure and signaling, a molecular link between
ankyrin-B and b-catenin, and evidence for targeted activation of the WNT/b-catenin pathway
as a potential treatment for this disease.
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Introduction
Arrhythmogenic cardiomyopathy (ACM) is an inherited arrhythmia 
syndrome (prevalence is estimated at 1:2000–5000) associated with 
fibrofatty replacement of the myocardium, malignant ventricular 
arrhythmias, and sudden cardiac death (1). The most common sub-
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tion, 45%–50%; global hypokinesis) and normal right ventricular 
systolic function. Cardiac MRI revealed similar biventricular dilation 
(Figure 1C) and additionally revealed scarring in the right ventricular 
free wall (Figure 1D) and left ventricular lateral wall (Figure 1E) and 
the “accordion sign” along the basal right ventricular free wall (Figure 
1C and ref. 16). Clinical genetic testing with pan-arrhythmia and car-
diomyopathy panels (79 genes; Supplemental Methods; supplemen-
tal material available online with this article; https://doi.org/10.1172/
JCI125538DS1) identified an AnkB-p.Glu1458Gly variant previously 
linked with AnkB syndrome (11). Aside from 2 TTN missense muta-
tions (p.Asp14812Val and p.Arg22397His) considered benign, no 
other rare variants were identified. The patient was noncompliant 
with exercise restriction and beta blockade, declined an implantable 
cardioverter defibrillator, and subsequently had a fatal cardiac arrest 
while running at 54 years of age.
Autopsy revealed a markedly enlarged heart (mass: 645 g; nor-
mal 342 ± 40 g) and no significant coronary atherosclerosis. On 
gross examination, the right ventricle was severely dilated, with 
free wall thinning to less than 0.1 cm and extensive translucent fat, 
whereas the left ventricle showed concentric hypertrophy (Figure 
1F). Histological analysis revealed that the right ventricular free 
wall had extensive fat infiltration of the muscle with widespread 
interstitial fibrosis (Figure 1G), whereas the left ventricle had 
focal fat deposits with interstitial fibrosis (Figure 1H). Analysis 
performed on right ventricular tissue from the deceased proband 
reconfirmed the AnkB-p.Glu1458Gly variant as loss of function. In 
addition to aberrant AnkB localization, we also observed loss of 
expression of the Na/Ca exchanger, an AnkB partner, at the plas-
ma membrane (Supplemental Figure 1, A and B).
Analysis of the proband’s family history revealed a paternal 
grandfather who died suddenly at 42 years of age, however, the 
circumstances were unknown and an autopsy was not performed 
(Supplemental Figure 2A, I-1). The parents and sister of the pro-
band declined an evaluation. Cascade screening identified the 
AnkB-p.Glu1458Gly variant in 1 of 3 daughters who, in marked 
contrast to her father, lived a sedentary lifestyle. Her clinical work-
up at 35 years of age was normal, showing no evidence of AnkB 
syndrome or ACM (Supplemental Figure 2A, IV-3).
Identification by exome sequencing of a novel ANK2 variant in 
an ARVC family. On the basis of the initial findings, we expanded 
our search for ANK2 variants in ACM. Six members from another 
ARVC family possessing 2 and 3 members with definite and border-
line Task Force Criteria–positive diagnoses of genotype-negative 
ARVC, respectively, underwent exome sequencing (Supplemen-
tal Figure 2B). The proband (Supplemental Figure 2B, III-5) was 
a previously healthy 41-year-old man who died suddenly shortly 
following intense aerobic exercise and was found to have ARVC 
on autopsy. Gross examination revealed a moderately dilated right 
ventricle with fibrofatty infiltration and localized thinning of the 
anterolateral aspects of the right ventricular free wall, whereas 
microscopic analysis revealed marked fatty myocardial infiltration, 
patchy interstitial fibrosis, and myocardial disorganization (Figure 
2, A–D). Molecular autopsy with a clinical ARVC genetic panel 
identified the DSG2-p.Val392Ile (Genome Aggregation Database 
[gnomAD] allele frequency: 0.26%) and DSC2-p.Leu732Val (gno-
mAD allele frequency: 0.12%) variants; neither was felt to be sole 
the culprit, given their gnomAD allele frequencies (17).
type involves the right ventricle and is termed arrhythmogenic right 
ventricular cardiomyopathy (ARVC), though left and biventricular 
forms are well described (2). Contemporary treatments for ACM, 
including antiarrhythmic drugs, catheter ablation, and implantable 
cardioverter defibrillators, attempt to suppress and treat malignant 
ventricular arrhythmias but fail to address the underlying pathophys-
iology of this progressive disease (3). The genetic culprits underlying 
ACM are gradually being identified and have offered critical clues 
into biological pathways, primarily linked to the desmosome, that 
may be operative in its pathogenesis (4–9). Although significant prog-
ress has been made since the original description of ARVC in 1982 by 
Marcus and colleagues (10), our understanding of the genetics and 
pathophysiology governing ACM remains incomplete.
Ankyrins are a family of proteins implicated in the membrane 
targeting of ion channels and transporters in both excitable and 
nonexcitable cells. Ankyrin-B (AnkB, encoded by ANK2) targets 
the Na/Ca exchanger and Na/K ATPase to the cardiac trans-
verse tubule network, and human ANK2 variants that affect AnkB 
expression or function are linked with a host of human arrhyth-
mias (11–14). Lack of global AnkB expression is neonatally lethal 
in mice (15). Thus, the in vivo role of AnkB in cardiac structural 
regulation is unknown, given the lack of a viable in vivo model.
Here, we report what we believe to be a novel mechanism 
for human ACM pathogenesis and provide evidence for a poten-
tial treatment strategy. Following identification of ANK2 loss-of-
function variants in patients with ARVC, development of a mouse 
model of cardiomyocyte-selective AnkB deletion revealed severe 
structural changes and premature death. Reflective of human dis-
ease, loss of AnkB in mice resulted in chamber remodeling, severe 
fibrosis, arrhythmia, heart failure, and early mortality. Further, we 
link AnkB in the hearts of both mice and humans with regulation 
of β-catenin, a molecule tightly associated with ACM pathogene-
sis (7). This pathway is selective, as we observed no effect of AnkB 
deficiency on the expression or localization of canonical ACM–
associated desmosomal proteins. SB-216763, an inhibitor of glyco-
gen synthase kinase-3β (GSK-3β) and pharmacological activator of 
the WNT/β-catenin pathway successfully prevented and rescued 
the ACM phenotype in vivo. Together, we believe our data identify 
ANK2 as a new, nonconventional ACM disease gene, define new 
cellular and organ roles for AnkB in cardiomyocytes and cardiac 
structural regulation and remodeling, and provide evidence to 
support GSK-3β inhibition as a potential therapy.
Results
Identification of ARVC on autopsy in a proband with AnkB syndrome. 
A 52-year-old previously healthy man receiving no medications was 
referred for a syncopal episode occurring at peak exertion. He had 
been running approximately 10 kilometers per day at high intensity 
for 20 years. A baseline ECG showed sinus bradycardia and a normal 
QT interval (Bazett corrected: 400 ms) in the setting of a prolonged 
QT(U) pattern (Figure 1A). Prior to referral to our clinic, he underwent 
an invasive electrophysiology study that failed to induce tachycardia. 
Exercise treadmill testing revealed intermittent pleiomorphic ven-
tricular couplets at peak exertion, and an implantable loop recorder 
revealed nonsustained polymorphic ventricular tachycardia (VT) 
during running (Figure 1B). Echocardiography showed moderate 
biventricular dilation, mildly reduced left ventricular (ejection frac-
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shared variants within 23 genes (Supplemental Table 1). Among 
these genes, only one, ANK2, had previously been implicated in 
either cardiac physiology or disease, and, correspondingly, the 
novel AnkB-p.Met1988Thr was considered the top candidate. All 
variants with allele frequencies of less than 5% identified from 
genes previously implicated in cardiomyopathy and arrhythmia 
and identified in the proband are listed in Supplemental Table 
2. The presence or absence of the p.Met1988Thr mutation was 
confirmed with Sanger sequencing in the affected and unaffect-
ed family members, respectively. Notably, the DSG2-p.Val392Ile 
and DSC2-p.Leu732Val variants also segregated with the ARVC 
phenotype in the pedigree. Analysis of autopsy tissue from the 
proband confirmed the AnkB-p.Met1988Thr variant as a loss-
of-function mutation associated with aberrant AnkB expression, 
reduced levels of the Na/Ca exchanger at the plasma membrane, 
and abnormal Z-line targeting (Supplemental Figure 1, A and C).
AnkB deficiency causes cardiac structural remodeling and prema-
ture death. To assess a potential role of AnkB in postnatal cardiac 
structure and function, we generated a mouse model of postnatal 
AnkB deletion in cardiomyocytes. Ank2fl/fl mice were generated, 
validated (described in Methods), and subsequently crossed with 
α–myosin heavy chain–Cre (αMHC-Cre) mice to selectively elim-
inate AnkB expression in cardiac myocytes (Supplemental Figure 
3A; αMHC-Cre Ank2fl/fl, referred to herein as Ank2 cardioselec-
tive–KO [Ank2-cKO] mice). Ank2-cKO mice were born at normal 
Mendelian ratios and, at 8 weeks of age, lacked structural or elec-
trical phenotypes. Immunoblots of cardiac and cerebellar lysates 
Cascade screening revealed that the proband’s 83-year-old 
father (Supplemental Figure 2B, II-12) had a right ventricular free 
wall aneurysm, mildly reduced right ventricular ejection fraction, 
and late potentials on signal-averaged ECG (SAECG), consistent 
with a definite ARVC diagnosis (1 major and 2 minor criteria). 
Evaluation of an asymptomatic 54-year-old paternal cousin (Sup-
plemental Figure 2B, III-1) revealed a normal 12-lead surface ECG, 
echocardiogram, and cardiac MRI. On exercise treadmill testing, 
he suffered a syncopal episode during the recovery period, and a 
4-lead surface ECG revealed superiorly directed wide complex 
tachycardia with a left bundle branch block pattern consistent 
with VT arising from the right ventricular apex (Figure 2E). These 
findings were consistent with a borderline diagnosis of ARVC (1 
major and 1 minor criteria). Two asymptomatic sisters of the pro-
band (Supplemental Figure 2B, III-2 and III-3) underwent clinical 
screening at 53 and 57 years of age and were found to have late 
potentials on SAECG, whereas the remainder of their workup was 
normal, corresponding to borderline ARVC diagnoses (1 major 
and 1 minor criteria). The remaining family members were either 
not accessible or declined evaluation.
Exome sequencing of the 5 aforementioned definite/bor-
derline ARVC family members and the unaffected mother of the 
proband identified shared variants within 11 genes with gnomAD 
allele frequencies of less than 0.005% that segregated with the 
familial phenotype (Supplemental Table 1). Since late potentials 
on SAECG may be a nonspecific finding, we performed a simi-
lar analysis excluding the sisters of the proband, which yielded 
Figure 1. Deceased proband harboring AnkB loss-of-function p.Glu1458Gly variant exhibits arrhythmogenic cardiomyopathy. (A) Surface 12-lead ECG. 
(B) Loop recording demonstrating nonsustained polymorphic VT. (C) Cardiac magnetic resonance short-axis image revealing moderate biventricular dila-
tion; the yellow ring highlights focal “crinkling” of the subtricuspid region of the right ventricular free wall consistent with the “accordion sign.” (D) Delayed 
enhancement imaging revealed scarring in the right ventricular (RV) free wall in a short-axis view (arrows) and (E) the left ventricular (LV) lateral wall 
(arrow) in a long-axis view. (F) Mid-transverse section of the autopsied heart revealing severe right ventricular dilation and wall thinning as well as concen-
tric hypertrophy of the left ventricle. Histology of the (G) right ventricle showing severe fibrofatty infiltration of the free wall in association with extensive 
ventricular interstitial fibrosis and (H) left ventricle showing moderate hypertrophy with focal areas of fibrofatty muscular infiltration and widespread 
interstitial fibrosis. Scale bars: 160 μm (G) and 60 μm (H).
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tinin, both key myocyte cytoskeletal molecules, was unchanged 
between control and Ank2-cKO hearts (Figure 4, A–D). Protein 
levels of key intercalated disc molecules, including plakoglobin, 
plakophilin-2, N-cadherin, desmoplakin, connexin-43, and des-
moglein-2, were unchanged between Ank2fl/fl and Ank2-cKO mice 
(Supplemental Figure 6, A–F). Disturbances in the cardiac sodium 
channel have been noted in samples from patients with ACM with 
diverse genetic causes (25), however, electrophysiological analysis 
of Nav1.5 using whole-cell patch clamping revealed no differenc-
es in cardiac sodium channel current (INa) peak current density, 
steady-state activation and inactivation kinetics, or recovery from 
inactivation (Supplemental Figure 7). Unexpectedly, β-catenin 
immunolocalization was significantly altered in Ank2-cKO hearts. 
In addition to decreased expression of β-catenin at the interca-
lated disc, we observed significant heterogeneity of the molecule 
across cardiac sections, as well as notable cytoplasmic puncta and 
lateralized expression (Figure 4E). In summary, Ank2-cKO ani-
mals display severe cardiac remodeling associated with aberrant 
β-catenin expression and localization in vivo.
Human hearts from deceased ANK2 ARVC probands display 
aberrant β-catenin localization. On the basis of the findings from 
our mouse model of AnkB deficiency, we investigated the local-
ization and organization of β-catenin in ventricular sections from 
nonfailing human heart, as well as in ventricular tissue from the 
deceased AnkB-p.Glu1458Gly and p.Met1988Thr probands. Con-
sistent with our findings in mice, we did not observe significant 
differences in desmin expression or localization when compar-
ing sections from nonfailing versus ARVC hearts (Supplemental 
Figure 8, H–J). Similar to our animal data, we observed abnormal 
distribution of β-catenin in the right ventricle of the ANK2 ARVC 
probands compared with distribution in nonfailing heart sections, 
including both loss and heterogeneous expression of β-catenin at 
the intercalated disc, as well as significant expression of β-catenin 
of Ank2-cKO mice confirmed the cardioselective deletion of AnkB 
(Figure 3A and Supplemental Figure 3, B and E–H). Further, con-
focal microscopy confirmed the absence of AnkB in cardiomyo-
cytes (Supplemental Figure 3, C and D). At rest, Ank2-cKO animals 
displayed sinus bradycardia (605 bpm vs. 665 bpm, P < 0.05), QT 
interval prolongation (0.020 s vs. 0.022 s, P < 0.05), and a trend 
toward QTc prolongation (Supplemental Figure 4, D, G, and H). 
Following catecholamine challenge (2.0 mg/kg epinephrine), 9 of 
10 Ank2-cKO mice had sustained ventricular arrhythmias (defined 
as lasting longer than 1 second), and 3 died during the stress proto-
col (Figure 3, D–F, and Supplemental Figure 4, A–C, I, and J).
Unlike normal littermates, Ank2-cKO mice showed severe 
cardiac remodeling beginning at 10 weeks of age. In Ank2-cKO 
mice, ventricular dilation associated with increased left ventricular 
end-systolic and -diastolic diameters was accompanied by reduced 
left ventricular ejection fraction and fractional shortening, reduced 
right ventricular fractional shortening, increased heart weight to 
tibia length ratio, and ultimately premature death (Figure 3, B–D 
and G, and Supplemental Figure 5). Ank2-cKO hearts showed gross 
right and left chamber dilation, wall thinning, and widespread car-
diac fibrosis consistent with human ACM phenotypes (Figure 3, 
H–K). We did not observe significant adipogenesis, however, fat-
ty infiltration is absent from most mouse models of ACM (18–23). 
Beyond the ventricle, we observed a marked enlargement of the 
atria compared with control mice (Figure 3, H and I).
AnkB deficiency alters β-catenin regulation. ACM is classically 
linked with molecular remodeling of the cardiac desmosome, a 
myocyte membrane domain evolved for both myocyte structural 
and electrical regulation (24). However, we observed no differ-
ence in the expression or localization of canonical desmosomal 
molecules, including desmoplakin, N-cadherin, connexin-43, 
or plakoglobin, between control and Ank2-cKO hearts (Figure 4, 
A–D). Further, we observed that expression of desmin and α- ac-
Figure 2. Deceased proband possessing AnkB loss-of-func-
tion p.Met1988Thr variant exhibits arrhythmogenic cardio-
myopathy. (A) Apical transverse section of the explanted 
heart of the deceased AnkB-p.Met1988Thr proband revealing 
fatty infiltration and localized thinning of the anterior and 
lateral aspects of the right ventricular free wall. Scale bar: 1 
cm. (B) Open view of the right ventricle revealing moderate 
dilation. Scale bar: 1 cm. Histology of the anteroapical right 
ventricular free wall at (C) ×1 and (D) ×40 original magnifica-
tion, revealing marked fatty infiltration of the myocardium 
with patchy interstitial fibrosis and myocardial disorgani-
zation. Scale bars: 5 mm (C) and 300 μm (D). (E) Four-lead 
surface ECG of paternal cousin following a treadmill test, 
revealing VT.
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mental Figure 8). A direct interaction of AnkB and β-catenin was 
further confirmed by in vitro binding assays, in which GST-AnkB 
MBD, but not GST, was associated with recombinant 35[S]-Met 
β-catenin (Supplemental Figure 8). Our findings illustrate a spe-
cific and direct interaction of the AnkB MBD and the C-terminal 
domain (CTD) of β-catenin (residues 697–781). It is important 
to note that, despite abnormal localization in Ank2-cKO hearts, 
full-length β-catenin protein levels were unchanged between 
Ank2-cKO and Ank2fl/fl control hearts (Figure 5, E and F). In sum-
mary, our findings indicate that a direct interaction with AnkB is 
required for normal β-catenin localization. These data support 
what we believe to be a novel role of AnkB in the regulation of car-
diac β-catenin signaling, as well as identify a potential new cellular 
mechanism underlying human ACM.
GSK-3β inhibitor prevents cardiac remodeling in an ACM mouse 
model. On the basis of our finding of a direct interaction between 
AnkB and β-catenin, coupled with prior studies demonstrating 
the importance of the WNT/β-catenin signaling pathway in ACM, 
in the myocyte cytoplasm (perinuclear; Figure 5, A and B). Loss of 
normal AnkB or β-catenin expression and localization was not a 
generalizable feature of an ARVC heart, as we observed normal 
localization and expression of both AnkB and β-catenin in hearts 
from patients with ACM secondary to either pathogenic PKP2 or 
PLN variants (Supplemental Figure 9). In summary, our results 
indicate that loss of AnkB and β-catenin localization is a feature 
unique to AnkB-linked ACM and provide a molecular rationale 
for cardiac remodeling associated with AnkB dysfunction.
AnkB and β-catenin are molecular partners. On the basis of our 
cellular data, we tested a potential molecular interaction of AnkB 
and β-catenin. Notably, AnkB and β-catenin interacted in co-IP 
experiments using detergent-soluble lysates of nonfailing human 
ventricle (Figure 5C and Supplemental Figure 8). Beyond co-IP 
experiments, glutathione S-transferase (GST) AnkB membrane–
binding domain (MBD), but not GST alone, was sufficient to 
associate with β-catenin from pull-down experiments using deter-
gent-soluble lysate from mouse ventricle (Figure 5D and Supple-
Figure 3. Cardiomyocyte-specific deletion of AnkB results in ventricular remodeling, cardiac arrhythmias, and reduced survival. Immunoblotting for AnkB 
(A) in heart tissue from Ank2-cKO (n = 4) and Ank2fl/fl (n = 5) mice (complete immunoblots are shown in Supplemental Figure 3). (B and C) Quantification 
of (B) left ventricular ejection fraction of Ank2fl/fl mice (n = 4) and Ank2-cKO mice (n = 9) and (C) right ventricular fractional shortening in Ank2fl/fl (n = 6) and 
Ank2-cKO (n = 7) mice. (D) Kaplan-Meier survival curves for Ank2fl/fl (n = 36) and Ank2-cKO (n = 69) mice. (E and F) Representative ECGs for Ank2-cKO mice 
following injection of 2.0 mg/kg epinephrine. Arrows denote (E) VT and (F) trigeminy. (G) Heart weight/tibia length (HW/TL) ratios of Ank2fl/fl (n = 8) and 
Ank2-cKO (n = 9) mice. (H and I) Representative Masson’s trichrome–stained whole slide views of (H) Ank2fl/fl and (I) Ank2-cKO and (J) magnified Ank2fl/fl and 
(K) Ank2-cKO hearts. Images are representative of 4 hearts from mice of each genotype. Scale bars: 2.5 mm (H and I) and 25 μm (J and K). Data represent the 
mean ± SEM. Statistical significance for A–C and G was determined using a 2-tailed parametric t test at 95% CI and a log-rank test for D.
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we tested whether the GSK-3β inhibitor SB-216763, an activator 
of the WNT/β-catenin pathway, is sufficient to prevent cardiac 
remodeling in Ank2-cKO mice when treatment is initiated at 4 
weeks of age (7, 20, 26). Notably, whereas vehicle-treated Ank2-
cKO mice showed significant age-dependent cardiac remodel-
ing, an increased heart weight/tibia length ratio, widespread car-
diac fibrosis, and a reduced ejection fraction, SB-216763–treated 
Ank2-cKO mice displayed cardiac phenotypes similar to those 
of control mice treated with SB-216763 or vehicle at 3 months of 
age (Figure 6, A, B, and D–K, and Supplemental Figure 10, A–P). 
Additionally, we observed no significant differences in the num-
ber of TUNEL-positive nuclei between Ank2fl/fl and Ank2-cKO 
mice treated with vehicle or SB-216763 (Supplemental Figure 
11, A–F). Consistent with the activity of GSK3β-inhibition, mice 
injected with SB-216763 showed reduced levels of cardiac phos-
phorylated β-catenin (p–β-catenin) (Figure 6C and Supplemen-
tal Figure 12, A and B). Both Ank2fl/fl and Ank2-cKO mice treated 
with SB-216763 had enhanced diffuse β-catenin signal, as seen 
Figure 4. Ank2-cKO murine hearts show misclocalization of β-catenin. 
Representative IF images of (A) desmin and N-cadherin, (B) plakoglo-
bin and α-actinin, (C) connexin-43 and α-actinin, (D) desmoplakin and 
α-actinin, and (E) AnkB and β-catenin in Ank2fl/fl and Ank2-cKO cardiac 
cryoslices. Staining was completed in tissue from 3 hearts for each stain, 
per genotype, with 3 images taken per heart. Scale bars: 20 μm.
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with immunofluorescence (IF), although in Ank2-cKO mice, 
failure to completely restore β-catenin localization to the inter-
calated disc was observed (Supplemental Figure 10, Q–T). Thus, 
GSK-3β inhibition is sufficient to prevent cardiac remodeling in 
the AnkB disease model.
GSK-3β inhibitor rescues cardiac function in an ACM-compro-
mised mouse model. Given the positive findings in the prevention 
study, we next tested whether GSK-3β inhibition is sufficient to 
reverse impaired cardiac function in Ank2-cKO mice with estab-
lished structural changes. As noted previously, 3-month-old 
Ank2-cKO mice showed marked structural remodeling, includ-
ing ventricular dilation, fibrosis, and reduced ejection fraction 
(Figure 3 and Supplemental Figure 5). Although ACM pheno-
types progressed in vehicle-treated Ank2-cKO mice, Ank2-cKO 
mice treated daily with SB-216763 starting at 3 months of age 
had an improved ejection fraction (Figure 7). In fact, following 
4 weeks of daily SB-216763 treatment, Ank2-cKO mice displayed 
structural phenotypes similar to those of control mice treat-
ed with SB-216763 or vehicle (P = NS). Ank2-cKO mice treated 
with SB-216763 trended toward a lower percentage of fibrosis, 
as quantified from Masson’s trichrome–stained cardiac sec-
tions, relative to mice treated with vehicle (0.99% vs. 0.31%, 
P = 0.08; Supplemental Figure 13, Q–U). Ank2-cKO mice treated 
with SB-216763 had an increased myocyte cross-sectional area 
compared with that of DMSO-treated mice (324.5 μm2 vs. 164.3 
μm2, P < 0.05; Figure 7, F–K). Thus, our findings illustrate that 
chronic GSK-3β inhibition is sufficient to both prevent and par-
tially reverse ACM phenotypes in the AnkB disease model.
Figure 5. AnkB and β-catenin are molecular partners. (A and B) Representative images of (A) plakoglobin and β-catenin staining from control and AnkB 
p.Met1988Thr human right ventricular tissue, and (B) β-catenin staining of control and AnkB p.Glu1458Gly human right ventricular tissue. Scale bars: 20 
μm. (C) Co-IP assay of AnkB IgG and β-catenin in human ventricular lysate. (D) GST-pulldown assay of in vitro–translated AnkB MBD and β-catenin in mouse 
cardiac lysate (complete images are shown in Supplemental Figure 8). The binding experiments were replicated 3 times. (E) Representative immunoblot of 
β-catenin and (F) quantification of full-length β-catenin in Ank2fl/fl (n = 4) and Ank2-cKO (n = 5) mouse cardiac lysate (complete images are shown in Supple-
mental Figure 8). Data represent the mean ± SEM. Statistical analysis for F was performed using a 2-tailed parametric t test at 95% CI. Binding assays were 
completed in triplicate.
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mAD, a total of 1895 missense, small insertion-deletion, or radi-
cal (defined as stop-gain, stop-loss, frameshift, or canonical splice 
site) ANK2 genetic variants with allele frequencies of less than 
0.1% are reported with an overall cumulative frequency of 9.0% 
(17). We observed no difference when the cumulative frequency of 
all missense, small insertion-deletion, or radical ANK2 rare vari-
ants was compared between the 2 cohorts (6.8% vs. 9%, P = 0.33).
Clinical features of probands possessing rare ANK2 variants. Clin-
ical features of the 13 ARVC probands harboring ANK2 variants 
from the multicenter ARVC cohort are summarized in Supplemen-
tal Table 6. The age of the probands at presentation ranged from 12 
to 59 years, 9 of 13 (69%) were male, and all were white. One pro-
band died suddenly and had ARVC confirmed on autopsy (AnkB-p.
Arg2069His), one had a successfully resuscitated, aborted cardiac 
arrest, and an additional nine probands had documented sustained 
monomorphic VT. Analysis of right ventricular free wall tissue 
from the deceased AnkB-p.Arg2069His proband revealed aberrant 
AnkB subcellular localization (Supplemental Figure 14). Beyond 
ventricular arrhythmias, 2 individuals were diagnosed with typical 
Identification of ANK2 rare variants in a genotype-negative 
ARVC cohort. We subsequently performed ANK2 genetic screen-
ing in a multicenter cohort of 207 unrelated genotype-negative, 
Task Force Criteria–positive (definite diagnosis) ARVC pro-
bands to further evaluate the contribution of ANK2 to ACM. 
The mean age of the study participants at presentation was 39.2 
years (SD: 14.3), 59.4% were male, 98.6% were white, and the 
mean number of major and minor Task Force Criteria was 1.9 
(SD: 0.8) and 1.6 (SD: 1.1), respectively. The remaining clinical 
characteristics are listed in Supplemental Table 3. A total of 14 
ANK2 rare variants (defined as minor allele frequency <0.1%) 
were identified among 13 individuals in the study cohort, cor-
responding to a cumulative carrier frequency of 6.8% (Supple-
mental Table 4). The allele frequencies, domain locations, and 
results of in silico analyses of the ANK2 variants are provided in 
Supplemental Table 5.
The cumulative frequency of the 14 rare variants identified 
in our ARVC cohort was increased relative to their cumulative 
frequency in gnomAD (6.8% vs. 0.7%, P < 0.001). Within gno-
Figure 6. GSK3-β inhibition is sufficient to prevent cardiac remodeling associated with cardiac deletion of AnkB. (A) Diagrammatic representation of GSK3-
βi prevention study in Ank2fl/fl and Ank2-cKO mice. Echocardiograms were performed at the time points indicated by arrows. (B) Heart weight/tibia length 
ratios. n = 3. (C) Levels of p–β-catenin by IB of Ank2-cKO cardiac tissue lysates. n = 3. (D and E) Ejection fraction and fractional shortening at baseline. Ejection 
fraction (F) and fractional shortening (G) after 8 weeks of drug therapy in vehicle- and GSK3-βi–treated Ank2fl/fl and Ank2-cKO mice in the prevention study. n 
= 5 (D and E) and n = 9 (F and G). (H) Representative Masson’s trichrome–stained heart sections from vehicle-treated Ank2fl/fl mice. (I) Ank2fl/fl GSK-βi–treated, 
(J) Ank2-cKO vehicle-treated, and (K) Ank2-cKO GSK3-βi–treated mice after 8 weeks of drug therapy in the prevention study. Scale bars: 25 μm (I–K). Images 
are representative of 2 hearts from mice of each genotype and treatment condition. Data represent the mean ± SEM. Statistical analysis for C was done with a 
2-tailed parametric t test at 95% CI. Statistical analysis for B and D–G was performed with a 2-way ANOVA followed by Tukey’s post hoc test.
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Our study was initiated following autopsy findings of severe 
ARVC in a sudden death victim who had a premortem clinical phe-
notype of AnkB syndrome secondary to the AnkB-p.Glu1458Gly 
variant. The ANK2 variant was considered an attractive candi-
date, given its established importance in cardiac disease, which 
has included robust evidence of genotype-phenotype segregation 
in large families and detailed in vitro and in vivo analyses of the 
underlying pathophysiology of ANK2 (11, 27). The significance of 
our initial finding was bolstered following identification of a nov-
el AnkB-p.Met1988Thr mutation segregating with an arrhythmic 
phenotype in a separate ARVC kindred using exploratory exome 
sequencing. Analyses of the hearts from the deceased probands 
of both families were consistent with AnkB loss of function. Nota-
bly, cardiac desmosomal structure and function appeared intact 
in both cases, suggesting a potential novel mechanistic pathway 
for ARVC development independent of the desmosome.
The importance of AnkB loss of function in relation to struc-
tural heart disease was subsequently supported by a cardioselec-
tive KO Ank2 mouse model that developed dramatic structural 
atrial flutter and had successful cavotricuspid isthmus ablations. 
None of the 13 probands was documented to have QT prolongation.
Although each individual was classified as genotype negative, 
3 had rare variants in cardiomyopathy genes (see Supplemental 
Table 6 for allele frequencies and in silico analyses). A desmosom-
al variant of unknown significance (DSP-p.Asn593Ser; gnomAD 
allele frequency = 0.05%) was observed in the proband possess-
ing the AnkB-p.Ile964Val variant. The MYH6 gene has not been 
implicated in ARVC, and a pathogenic SCN5A-p.Phe861Trpf-
sTer90 mutation was identified in the proband possessing the 
AnkB-p.Thr3744Asn variant.
Discussion
Here, we provide the first evidence to our knowledge implicating 
AnkB loss of function in structural heart disease and ACM; iden-
tify a mechanistic rationale involving β-catenin signaling through 
a previously unknown AnkB interaction that appears independent 
of the desmosome; and demonstrate that GSK-3β inhibition is able 
to both prevent and rescue the phenotype.
Figure 7. GSK3-β inhibition is sufficient to reverse cardiac remodeling associated with cardiac deletion of AnkB. (A) Diagrammatic representation 
of the GSK3-βi rescue study involving Ank2fl/fl and Ank2-cKO mice. Echocardiograms were performed at the time points indicated by arrows. Ejection 
fraction (B) and fractional shortening (C) at 12 weeks of age and ejection fraction (D) and fractional shortening (E) after 4 weeks of drug therapy in 
vehicle- and GSK3-βi–treated Ank2fl/fl and Ank2-cKO mice. n = 3 (B–E). (F and G) Myocyte cross-sectional area in Ank2fl/fl (n = 3 for each treatment) and 
Ank2-cKO (n = 3 for each treatment) mice following treatment with vehicle or GSK3-βi. (H–K) Representative cross-sectional images of Ank2fl/fl and 
Ank2-cKO hearts following vehicle and GSK3-βi therapy. Images are representative of 3 hearts from mice of each genotype and treatment condition. 
Scale bars: 25 μm. Data represent the mean ± SEM. Statistical analysis for B–F was performed with a 2-way ANOVA followed by Tukey’s post hoc test.
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ACM initially present with marked structural changes. Although 
implantable cardioverter defibrillators can be life-saving and anti-
arrhythmic drugs and catheter ablation may be effective in sup-
pressing malignant ventricular arrhythmias, there are no available 
therapies that directly target the underlying pathophysiology of 
ACM (3). The ability to halt and reverse progression of the disease 
through targeted medical therapy would be a critical advance for 
patients with ACM. It should be noted that SB-216763, as a com-
pound that upregulates WNT signaling, has a theoretical risk of 
oncogenesis, though, to our knowledge, no oncogenic signals have 
been noted in murine or zebrafish models to date (20, 26). None-
theless, it may be necessary to pursue alternative therapeutic com-
pounds and strategies to target this pathway.
Although the cumulative allele frequency of the 14 variants 
in our multicenter ARVC cohort exceeded that in gnomAD, the 
cumulative frequency of all ANK2 rare variants anticipated to 
be functional did not differ between the 2 cohorts. It is conceiv-
able that the ANK2 variants identified in our cohort are unique 
in their ability to predispose patients to ARVC, however, the lack 
of enrichment observed when all ANK2 variants were considered 
may also be secondary to inadequate statistical power, provided a 
true association exists, or may suggest that disease-relevant ANK2 
variants require additional genetic and/or environmental insults, 
such as intense endurance exercise, to cause an ACM phenotype 
(32). This concept is further supported by the allele frequencies of 
many ANK2 variants identified being too common to be causative 
in isolation, coupled with the frequent lack of family history in cas-
es. Although potentially viewed as a limitation, this phenomenon 
is probably operative in the majority of genetic ACM subtypes, 
in which the importance of polygenic drivers and gene dosage 
is becoming increasingly apparent (33–36). Indeed, the notion 
of ACM being a polygenic disease dependent on multiple “hits” 
will almost certainly be the rule rather than the exception for the 
vast majority of remaining ACM genotype–negative cases that are 
overwhelmingly sporadic (37).
Limitations. As noted above, although the clinical and patholog-
ical phenotypes in this study are striking and decisive, future work 
will be necessary to clarify the role of genetic and environmental 
modifiers contributing to an ACM phenotype in the setting of a 
pathogenic ANK2 variant. Next-generation sequencing techniques 
have provided an abundance of genetic data, however, we still lack 
a detailed understanding of vast noncoding regions of the genome 
that will influence disease phenotypes. Although AnkB dysfunction 
— whether via promoter variants that reduce expression (14), loss-
of-function variants that either disrupt tissue expression or cellular 
function (12, 27, 38), or chromosomal reorganization that affects 
AnkB expression and activity (39) — is linked with human disease 
phenotypes, the penetrance and severity of cardiac phenotypes is 
often variable. Further detailed evaluation of individuals in this 
study, as well as others, will likely elucidate more complete genet-
ic and environmental profiles underlying the disease and disease 
penetrance. Future studies utilizing AnkB-p.Glu1458Gly– or p.Met-
1988Thr-knockin models may also provide additional mechanistic 
data underlying ACM pathogenesis due to AnkB loss of function.
Conclusions. We believe our study identifies a novel genet-
ic culprit and molecular pathway for ACM and provides the first 
evidence to implicate AnkB in the development of structural heart 
abnormalities by 10 weeks of age, including marked biventricular 
dilation, fibrosis, and reduced ejection fraction, despite apparent-
ly preserved desmosomal structure and function. Fat deposition 
is a hallmark of ACM in humans (28), however, its presence in 
murine models of disease is variable. Numerous genetic models 
of ACM, including those involving plakoglobin, plakophilin-2, and 
desmoglein-2, have failed to demonstrate adipocyte infiltration 
(18–23). Thus, the absence of fatty infiltration in Ank2-cKO hearts 
was not unexpected. The precise mechanisms underlying reduced 
cardiac function in the Ank2-cKO mice remain to be determined, 
and we acknowledge that future experiments will be necessary to 
dissect the culprit molecular and cellular pathways and to further 
our understanding of the therapeutic effect of SB-216763.
Our findings of a direct interaction between AnkB and β-cat-
enin and heterogeneous expression patterns of β-catenin observed 
in the hearts of the Ank2-cKO mice and deceased human probands 
provide support for altered β-catenin homeostasis as a mecha-
nism for the observed structural remodeling. These data are fur-
ther supported by our findings that GSK-3β inhibition is effective 
at both preventing and reversing the cardiac structural and tissue 
remodeling in Ank2-cKO animals. AnkB in this novel role may also 
impact β-catenin indirectly by altering the phosphorylation status 
of β-catenin through AnkB interactions with protein phosphatase 
2A (29, 30). Although we have hypothesized that altered β-caten-
in may serve to promote cardiomyopathy, other molecular factors 
may support structural remodeling in the Ank2-cKO mouse mod-
el. Certainly, chronic altered calcium handling observed in AnkB 
disease may alter both transcriptional and structural program-
ming in the heart. Further, ankyrins are associated with a host of 
structural and signaling proteins in heart and other excitable tis-
sues that may affect disease progression. Importantly, we hypoth-
esize that altered β-catenin localization produces a phenotype 
unique from that of simple β-catenin deficiency. Notably, a model 
of inducible β-catenin deletion in the adult mouse does not display 
cardiac phenotypes, although the model is based on phenotypes in 
an acute (4-week-KO) and unstressed animal (31).
The decision to trial SB-216763, a GSK-3β inhibitor and phar-
macological activator of the WNT/β-catenin pathway, as a treat-
ment was driven by prior studies involving zebrafish and murine 
models of ACM, coupled with the findings in our current study (20, 
26). As a preventive therapy administered from 4 weeks of age, a 
time point that precedes the development of structural changes, 
its efficacy was remarkable, with the cardiac phenotype of Ank2-
cKO mice at 3 months of age being indistinguishable from that 
of their healthy Ank2fl/fl counterparts. Perhaps even more strik-
ing was the ability to partially reverse the ACM phenotype when 
administration was initiated after marked structural changes had 
already developed. Despite the presence of severe biventricular 
dilation, fibrosis, and reduced ejection fraction in 3-month-old 
mice, following 1 month of SB-216763 administration, the cardi-
ac phenotype returned to near normal. Given the increased myo-
cyte cross-sectional area observed following administration of 
SB-216763, we hypothesize that the improved ventricular function 
was mediated through hypertrophy and increased contractility 
of surviving myocytes. To our knowledge, this is the first study to 
show the ability of SB-216763 to ameliorate an ACM phenotype 
in mice and is a critical finding, given that many patients with 
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Immunostaining. For cryoslices and paraffin-embedded tissue, 
heart sections from Ank2fl/fl, Ank2-cKO, and human cardiac tissue 
were cut at 5-μm thickness, blocked in blocking solution (3% fish 
gelatin, 0.1% DMSO, 0.075% Triton X-100), and then incubat-
ed overnight at 4ºC. Paraffin sections were deparaffinized using 
xylenes and ethanol, and antigens were retrieved using pepsin solu-
tion for 15 minutes at 37°C. After secondary antibody treatment, the 
sections were extensively washed and covered with VECTASHIELD 
imaging medium (Vector Laboratories), and coverslips (no. 1) were 
applied. Images were acquired with a confocal microscope (510 
Meta, Carl Zeiss) with a 40× water 1.30 NA lens (pinhole equals 1.0 
airy disc; Carl Zeiss) and imaging software (release version 4.0 SP1; 
Carl Zeiss). The images were collected using similar confocal proto-
cols at room temperature.
Antibodies. The antibodies used included the following: AnkB 
(1:2000 immunoblotting [IB], 1:100 IF, custom-made by Covance); 
β-catenin (1:1000 IB, 1:100 IF; BD Biosciences, 610153); α-actinin 
(1:400 IF; MilliporeSigma); desmoplakin (1:1000 IB, 1:100 IF; Abcam, 
ab16434); N-cadherin (1:1000 IB, 1:100 IF; Thermo Fisher Scientific, 
33-3900); desmin (1:200 IF; MilliporeSigma, D8281); plakoglobin 
(1:1000 IB, 1:100 IF; Abcam, 15153); desmoglein-2 (1:1000, IB; Invi-
trogen, Thermo Fisher Scientific, 69369); connexin-43 (1:1000, IB, 
1:100 IF; Thermo Fisher Scientific, 71-0700); p–β-catenin (1:1000 
IB; Cell Signaling Technology, 9561); GAPDH (1:10,000 IB; Fitzger-
ald); and βII spectrin (1:100 IF; Covance). Secondary antibodies for IB 
included donkey anti–mouse HRP and donkey anti–rabbit HRP (The 
Jackson Laboratory) as well as goat anti–mouse and goat anti–rabbit 
StarBright 700 Fluorescent Secondary Antibodies (Thermo Fisher 
Scientific). Secondary antibodies for IF included anti–rabbit and anti–
mouse Igs conjugated to Alexa Fluor 488 or Alexa Fluor 568 (1:400; 
Invitrogen, Thermo Fisher Scientific). BD Biosciences produced the 
β-catenin antibody against the 571–781 amino acids of the murine 
β-catenin protein, which corresponds to the 11th and 12th armadillo 
repeats (ARMs) and the C-terminal portion of the protein.
β-Catenin antibody validation. HEK293 cell lysates were gathered, 
subjected to SDS-PAGE, transferred to a nitrocellulose membrane, 
and probed with β-catenin antibody.
Echocardiography. Transthoracic echocardiography was per-
formed using the Vevo 2100 (VisualSonics). The mice were anes-
thetized using 2.0% isoflurane in 95% O2 and 5% CO2 at a rate of 
approximately 0.8 L/min. Anesthesia was maintained by adminis-
tration of oxygen and approximately 1% isoflurane. Electrode gel 
was placed on the ECG sensors of the heated platform, and the 
mouse was placed supine onto the platform to monitor electrical 
activity of the heart. A temperature probe was inserted into the rec-
tum of the mouse to monitor its core temperature of approximately 
37°C. The MS-400 transducer was used to collect the contractile 
parameters and chamber dimensions of the left ventricle using 
M-mode in the short axis. For assessment of the right ventricle, 
fractional shortening and chamber dimensions were evaluated in a 
modified long axis of the heart (40). 2D images were obtained for 
confirmation of proper orientation.
Mortality studies. Survival of Ank2-cKO mice (n = 69) mice was 
compared with that of Ank2fl/fl animals (n = 36). Mice in this study were 
followed for 12 months or until death, whichever came first. Mice were 
allowed to run freely in cages but were not subjected to secondary 
exercise or environmental protocols.
disease. Our findings provide insight into the underlying mech-
anism, which appears to be mediated through WNT/β-catenin 
signaling secondary to a novel AnkB–β-catenin interaction that 
is independent of the cardiac desmosome. Last, we provide evi-
dence to support GSK-3 inhibition as a therapy capable of both pre-
vention and rescue of the ANK2-mediated ACM phenotype.
Methods
Study population. The initial proband for this study underwent clinical 
evaluation, management, and subsequent autopsy at the UCSF Med-
ical Center. Clinical and genetic cascade screening was performed in 
consenting first-degree family members.
Whole-exome sequencing in a multigenerational ARVC kindred. 
Selected affected and unaffected members of a multigenerational 
genotype-negative ARVC kindred underwent whole-exome sequenc-
ing for gene discovery. Whole-exome sequencing was performed for 
5 definite or borderline (as defined by the Task Force Criteria) affect-
ed individuals and 1 unaffected family member; sequencing and 
bioinformatic methods are provided in the Supplemental Methods. 
Shared variants with allele frequencies of less than 0.005%, as found 
in gnomAD, were filtered to generate a candidate gene list. The top 
candidate was selected on the basis of biological plausibility, and its 
segregation among family members was then confirmed with Sanger 
sequencing. All variants with allele frequencies of less than 5% identi-
fied from genes previously implicated in cardiomyopathy and arrhyth-
mia identified in the proband are provided in Supplemental Table 2.
Ank2-cKO mice. Ank2-cKO mice were generated by the introduc-
tion of LoxP sites flanking exon 24 of the ANK2 gene. This strategy 
results in the deletion of 73 bp of coding sequence: the splicing of exon 
23 to exon 25 leads to a frameshift resulting in a premature stop codon 
in exon 25. Mice were crossed to generate pure lines of floxed mice 
devoid of the neomycin cassette. Mice were screened by PCR and 
Southern blot analysis (genOway). Mice were backcrossed onto a C57/
BL6 background more than 5 times. Animals were crossed with mice 
expressing the Cre recombinase under the cardiac αMHC, resulting in 
specific loss of AnkB in adult cardiac myocytes.
Animals. All mice used were male and female littermates 
between 4 and 16 weeks of age, with the exception of those allowed 
to live up to 1 year as part of the survival studies. The mice were 
housed in the same facility, consumed the same diet, provided water 
ad libitum, and kept on identical 12-hour light/12-hour dark cycles. 
Supplemental Table 7 delineates the sex and age of all mice used in 
physiological experiments.
Immunoblots. Murine tissue was harvested and immediately 
placed into cold NP-40 substitute homogenization buffer. Follow-
ing protein quantification, lysates were boiled for 5 minutes at 95°C 
in 20:1 Laemmli sample buffer (Bio-Rad) and β-mercaptoethanol 
and electrophoresed on a Mini-PROTEAN Tetra Cell (Bio-Rad) on a 
4%–15% precast gel (Bio-Rad). Following transfer to nitrocellulose, 
the membranes were blocked for 30 minutes using either 3% BSA or 
5% blocking buffer (Bio-Rad), depending on the protein of interest. 
Next, the membranes were incubated with a primary antibody over-
night and then washed and incubated with a secondary antibody for 2 
hours. Densitometric analysis was performed using ImageJ software 
(NIH). For all experiments, protein values were normalized against 
an internal loading control (GAPDH) or against total protein loading 
quantification via Ponceau staining.
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thawing. The crude extract was suspended in a solution of PBS, 1 mM 
DTT, 1 mM EDTA, 40 g/mL 4-benzenesulfonyl fluoride hydrochlo-
ride (AEBSF), 10 g/mL benzamide, and 10 g/mL pepstatin. Lysates 
were homogenized by sonication and centrifuged to remove cellular 
debris, and the supernatant was incubated with glutathione-sepharose 
beads overnight at 4°C. A small amount was separated by SDS-PAGE 
and stained with Coomassie blue to quantitate immobilized protein.
In vitro binding assays. In vitro direct binding assays were per-
formed as previously described (17) using GST fusion proteins and 
35S-Met–labeled in vitro translation products. Reactions were per-
formed at 4°C for 3 hours in a high-stringency binding buffer (50 mM 
Tris, pH 7.4, 1 mM EDTA, 1 mM EGTA, 500 mM NaCl, 0.1% Triton 
X-100), washed 3 times with a high-stringency wash buffer (1 M NaCl 
binding buffer), separated by SDS-PAGE, and visualized by phospho-
imaging. In the non–35S-Met–labeled GST pulldown, a 250-mM NaCl 
wash buffer was used.
Co-IP experiments. Mouse heart samples were flash-frozen in liq-
uid nitrogen. Samples were resuspended in homogenization buffer and 
further homogenized by mechanical agitation with a Dounce homoge-
nizer. Lysates were centrifuged for 15 minutes at 14,000 ×g. The result-
ing supernatant was incubated with 5 μl anti–AnkB Ig at 4°C overnight. 
Each sample (15 μg) was set aside to be used as an input loading con-
trol. After overnight incubation, the supernatant was removed from the 
beads, and the beads were washed 3 times with wash buffer (1× PBS, 
0.1% Triton X-100, and 150 mm NaCl) before immunoblotting with 
β-catenin (1:1000 IB, 1:100 IF; BD Biosciences, 610153).
SB-216763 prevention and reversal studies. Ank2fl/fl and Ank2-cKO 
animals underwent daily intraperitoneal injections of 2.5 mg/kg 
SB-216763 dissolved in DMSO. Vehicle-treated animals were inject-
ed with an equivalent volume of DMSO alone. Low-volume HPLC 
syringes (Hamilton) were used, such that total injection volumes were 
less than 15 μL. Drug and vehicle injections were initiated in mice at 4 
weeks of age in the prevention studies and performed until 12 weeks 
of age, whereas they commenced in mice at 12 weeks of age in the 
reversal studies and were continued for 4 weeks. In both instances, the 
echocardiography operator was blinded to genotype and treatment, 
whereas the administrator of therapy was not.
ANK2 analysis in the international multicenter ARVC cohort. An 
international multicenter cohort consisting of genotype-negative, 
Task Force Criteria–positive ARVC patients (meeting the criteria for 
“definite”) underwent screening for the ANK2 gene. The cohort was 
made up of patients from the following institutions and registries: 4 
North American and European medical centers: Johns Hopkins Med-
ical Center (Baltimore, Maryland, USA); Academic Medical Cen-
tre (Amsterdam, Netherlands); Toronto General Hospital (Toronto, 
Ontario, Canada); University Hospital Linköping (Linköping, Swe-
den); and 2 registries (Familial Cardiomyopathy Registry, University 
of Colorado and the Canadian ARVC Registry). “Genotype nega-
tive” was defined as the absence of a suspected pathogenic mutation 
within 1 of the 5 desmosomal genes (PKP2, DSC2, DSG2, DSP, JUP) 
and TMEM43. Participant demographics and medical details were 
obtained through review of medical records.
All study participants underwent next-generation sequencing of 
the 53 exons comprising the ANK2 gene; sequencing and bioinformatic 
methodology for each site are provided in the Supplemental Methods. 
All identified rare ANK2 variants, defined as an allele frequency of less 
than 0.1% observed in gnomAD and anticipated to be functional (mis-
Tissue pathology for hearts from mice and deceased human probands. 
Whole hearts were excised from 2- to 3-month-old male Ank2fl/fl and 
Ank2-cKO mice, whereas the hearts from the deceased human pro-
bands who had the AnkB-p.Glu1458Gly and -p.Met1988Thr muta-
tions were obtained at the time of autopsy. Hearts were rinsed in PBS, 
fixed in 10% formalin solution, and then paraffin embedded. Hearts 
were sliced at 5-μm thickness and stained with Masson’s trichrome at 
The Ohio State University’s murine pathology core laboratory. Whole 
heart images were obtained using the PathScan Enabler IV slide imag-
er (Meyer Instruments), and magnified images were acquired with a 
Thermo Fisher Scientific EVOS microscope. Human samples for Sup-
plemental Figure 8 were derived from 4 ACM probands (with patho-
genic variants in either PKP2 or PLN) and 5 control hearts. None of the 
4 ACM patients had the aberrancies that were observed in the ANK2 
variant carriers. These human cardiac specimens were obtained from 
the cardiac tissue bank of the Department of Pathology at the Univer-
sity Medical Center (Utrecht, Netherlands). The scientific advisory 
board of the University Medical Center Utrecht (Biobank) approved 
this component of the study.
Myocyte cross-sectional area analysis. Images of cross-sectional 
myocytes from H&E-stained murine cardiac sections were obtained 
using a Thermo Fisher Scientific EVOS microscope. ImageJ software 
(NIH) was used to determine the cross-sectional area of 50 myocytes 
per heart section.
TUNEL analysis. TUNEL staining was performed using a Fluo-
rescein In Situ Cell Death Detection Kit (Roche, 11684795910), and 
TUNEL-stained cardiac sections were imaged using an EVOS micro-
scope. TUNEL-stained images were analyzed using ImageJ (NIH) 
with “color threshold” and “analyze particle” functions. Only particles 
of greater than 150 pixels in size were counted as nuclei. The numbers 
of TUNEL-positive nuclei were normalized to total nuclei (DAPI).
Electrophysiological studies of Nav1.5. Sodium current recordings 
were conducted in a low-sodium extracellular solution containing 
10 mM NaCl, 1 mM MgCl2, 1.8 mM CaCl2, 0.1 mM CdCl2, 20 mM 
HEPES, 127.5 mM CsCl, and 11 mM glucose. The pipette solution con-
tained 5 mM NaCl, 135 mM CsF, 10 mM EGTA, 5 mM MgATP, and 
5 mM HEPES. To characterize the voltage dependence of the peak 
INa, single cells were held at –120 mV, and 200 msec voltage steps 
were applied from −100 to +10 mV in 5-mV increments. The interval 
between voltage steps was 3 seconds. Voltage dependence of inacti-
vation was assessed by holding cells at various potentials from −160 
to −40 mV, followed by a 30-msec test pulse to −40 mV to elicit INa. 
Recovery from inactivation was studied by holding cells at −120 mV 
and applying two 20-msec test pulses (S1, S2) to −40 mV separated by 
increments of 1 msec to a maximum S1–S2 interval of 50 msec. The 
S1–S1 interval was kept constant at 3 seconds.
Production and purification of fusion proteins. cDNAs for the AnkB 
MBD, spectrin-binding domain (SBD), and CTD were PCR ampli-
fied, subcloned into pGEX6P-1, and sequenced to confirm correct 
sequences. BL21(DE3)pLysS cells were transformed with the various 
AnkB pGEX6P1 constructs and grown overnight at 37°C in lysoge-
ny broth (LB) supplemented with 0.1 g/L ampicillin. The overnight 
cultures were subcultured for large-scale expression. The bacterial 
cells were grown to an OD of 0.6 and induced with 1 mM isopropyl 
1-thio-α-D-galactopyranoside (IPTG) for 4 hours at 37°C. Cells were 
centrifuged for 10 minutes at 8000 ×g, resuspended in PBS, and fro-
zen at –20°C following resuspension. Lysis of cells was achieved by 
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analyzed clinical and/or genetic data. RMH, ERL, CAJ, CFK, 
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sense, nonsense, and splice site variants, along with small insertion-de-
letions), were confirmed with Sanger sequencing. In silico prediction 
of the functional effects of missense mutations was examined using 
Polymorphism Phenotyping v2 (PolyPhen-2), Sorting Intolerant From 
Tolerant (SIFT), MutationTaster, and Combined Annotation-Depen-
dent Depletion (CADD) (41–44). The collective prevalence of ANK2 rare 
variants identified in the multicenter ARVC cohort was compared with 
their cumulative prevalence and the cumulative prevalence of all ANK2 
rare variants anticipated to be functional, as defined above, in gnomAD.
Statistics. Normally distributed continuous variables are present-
ed as the mean ± SD for clinical data and the mean ± SEM for in vitro 
and in vivo analyses. P values were determined with the unpaired, 
2-tailed Student’s t test for single comparisons of normally distributed 
continuous variables, and the Fisher’s exact test was used for compar-
isons of categorical values. Multiple comparisons were analyzed with 
ANOVA. Tukey’s test was used for post hoc analyses. If the data distri-
bution failed normality tests with the Shapiro-Wilk test, a rank-based 
ANOVA and Dunn’s multiple comparisons test were performed. P val-
ues in the survival study were determined using the log-rank test. Sta-
tistical analyses were performed using R and GraphPad Prism. P val-
ues of less than 0.05 were considered statistically significant. At least 
3 images were gathered for IF images from proband patient samples. 
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